Clinical trials: Naltrexone
Malignant Glioma
Low Dose Naltrexone for Glioma Patients
To compare the effects of low dose naltrexone (LDN) versus placebo on quality of life in high grade glioma patients undergoing standard chemoradiation
- Trial name
- NCT01303835
- Testing
- LDN
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Katy Peters
Heroin Dependence, Opioid Dependence
Biomarkers of Injectable Extended Release Naltrexone Treatment
This study evaluates the biological markers of treatment of opioid dependent individuals with an extended release formulation of the opioid antagonist naltrexone.
- Trial name
- NCT02324725
- Testing
- Naltrexone
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Pennsylvania
Alcoholism, Eating Disorder
Naltrexone Treatment for Alcoholic Women
This study will assess naltrexone's effectiveness in treating alcoholism in women and provide information on its potential value in treating eating disorders common among alcoholic women.
- Trial name
- NCT00000448
- Testing
- naltrexone
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Yale University
Gulf War Illness
Trial of Naltrexone and Dextromethorphan for Gulf War Illness
Veterans of the 1991 Gulf War who developed Gulf War Illness are being studied. Treatments with FDA approved generic drugs are being administered to see if they help with the symptoms of Gulf War Illness, such as chronic fatigue…
- Trial name
- GWI Treatment (NCT02206490)
- Testing
- naltrexone, Dextromethorphan
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- East Carolina University
Nicotine Dependence, Alcohol Use Disorder
Combining Varenicline and Naltrexone for Smoking Cessation
This study is a double-blind, randomized clinical trial using a two group medication design consisting of the combination of VAR (1 mg twice daily) + NTX (50 mg once daily) and VAR (1 mg twice daily) + PLA (matched to NTX), for…
- Trial name
- NCT02698215
- Testing
- Varenicline, Varenicline plus Naltrexone
- Where
- United States
- Volunteers
- 165 people
- Sponsor
- University of California, Los Angeles
Breast Cancer
Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Naltrexone may fight breast cancer by blocking the use of estrogen by the tumor cells.
- Trial name
- NCT00379197
- Testing
- naltrexone, PET scan
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Metastatic Prostate Cancer
Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)
The study is being done to see if a small daily dose of naltrexone (LDN, 3 mg pill) can help reduce tiredness (fatigue) in men with prostate cancer.
- Trial name
- NCT07224009
- Testing
- Naltrexone
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Arkansas
Alcohol Dependence, Alcohol Use Disorder
Extended-release Naltrexone and Care Management for Alcohol Dependent Frequent Emergency Department Users
Our primary aim is to assess the feasibility of initiating treatment in the ED with extended-release naltrexone (XR-NTX) plus care management (CM) vs.
- Trial name
- NCT02445339
- Testing
- XR-NTX+CM (Extended-Release Naltrexone plus Care Management)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- NYU Langone Health
Obesity
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
A randomized, double-blinded, placebo controlled study intended to capture cardiovascular outcomes during real-world use of naltrexone/bupropion (NB).
- Trial name
- INFORMUS (NCT06098079)
- Testing
- Naltrexone-Bupropion (NB) Combination
- Where
- 140 sites in United States
- Volunteers
- 8,600 people
- Sponsor
- Currax Pharmaceuticals
Schizophrenia, Psychotic Disorders
Augmenting Zyprexa With Naltrexone to Ameliorate Metabolic Side-Effects
The main purpose of this study is to determine whether the opioid antagonist naltrexone is helpful in ameliorating the weight gain and other adverse metabolic side effects experienced by schizophrenic patients taking the second…
- Trial name
- Zyprexa (NCT00567034)
- Testing
- naltrexone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mclean Hospital
Opioid Intoxication
The Evaluation of Safety and Tolerance of Commercially Available Naltrexone Administered Daily - Assessment for CBRN Operations
The objective of this study is to evaluate the tolerance and safety of naltrexone while performing military specific tasks, and to assess plasma concentrations following naltrexone, administered orally at 50 mg per day for 7…
- Trial name
- TEST CANADA (NCT03879460)
- Testing
- Naltrexone Hydrochloride
- Where
- Canada
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Timothy Smith
Opioid-Related Disorders
Youth Opioid Recovery Support: Improving Care Systems
Opioid addiction, also referred to as opioid use disorder, among young people is a growing health concern for patients and their families.
- Trial name
- YORS (NCT04015115)
- Testing
- Youth Opioid Recovery Support service model
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Complex Regional Pain Syndrome
Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome
The investigators are testing treatment with low-dose naltrexone (LDN) for symptom relief of complex regional pain syndrome (CRPS).
- Trial name
- LDN-CRPS (NCT02502162)
- Testing
- LDN
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Stanford University
Opioid-use Disorder
A Strategy to Improve Success of Treatment Discontinuation in Buprenorphine Responders
This study is an open--label randomized outpatient trial to evaluate feasibility and efficacy of rapid buprenorphine (BUP) discontinuation followed by brief course of treatment with long--acting naltrexone (XR--NTX) and to…
- Trial name
- NCT03232346
- Testing
- Vivitrol, Buprenorphine
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute